tbuckley/cabot-search huggingface dataset:
Concurrence of bullous pemphigoid and herpetiform pemphigus with IgG antibodies to desmogleins 1/3 and desmocollins 1-3
Authors: C. Ohata, H. Koga, K. Teye, N. Ishii, T. Hamada, T. Dainichi, M. Furumura, M. Sato, H. Sueki, T. Hashimoto
Journal: British Journal of Dermatology (2012)

Journal Article Concurrence of bullous pemphigoid and herpetiform pemphigus with IgG antibodies to desmogleins 1/3 and desmocollins 1–3 Get access C. Ohata, C. Ohata Department of Dermatology, Kurume University School of Medicine, and Kurume University Institute of Cutaneous Cell Biology, Fukuoka, Japan Search for other works by this author on: Oxford Academic Google Scholar H. Koga, H. Koga Department of Dermatology, Kurume University School of Medicine, and Kurume University Institute of Cutaneous Cell Biology, Fukuoka, Japan Search for other works by this author on: Oxford Academic Google Scholar K. Teye, K. Teye Department of Dermatology, Kurume University School of Medicine, and Kurume University Institute of Cutaneous Cell Biology, Fukuoka, Japan Search for other works by this author on: Oxford Academic Google Scholar N. Ishii, N. Ishii Department of Dermatology, Kurume University School of Medicine, and Kurume University Institute of Cutaneous Cell Biology, Fukuoka, Japan Search for other works by this author on: Oxford Academic Google Scholar T. Hamada, T. Hamada Department of Dermatology, Kurume University School of Medicine, and Kurume University Institute of Cutaneous Cell Biology, Fukuoka, Japan Search for other works by this author on: Oxford Academic Google Scholar T. Dainichi, T. Dainichi Department of Dermatology, Kurume University School of Medicine, and Kurume University Institute of Cutaneous Cell Biology, Fukuoka, Japan Search for other works by this author on: Oxford Academic Google Scholar M. Furumura, M. Furumura Department of Dermatology, Kurume University School of Medicine, and Kurume University Institute of Cutaneous Cell Biology, Fukuoka, Japan Search for other works by this author on: Oxford Academic Google Scholar M. Sato, M. Sato Department of Dermatology, Showa University Fujigaoka Hospital, Kanagawa, Japan Search for other works by this author on: Oxford Academic Google Scholar H. Sueki, H. Sueki Department of Dermatology, Showa University Fujigaoka Hospital, Kanagawa, Japan Search for other works by this author on: Oxford Academic Google Scholar T. Hashimoto T. Hashimoto Department of Dermatology, Kurume University School of Medicine, and Kurume University Institute of Cutaneous Cell Biology, Fukuoka, Japan T. Hashimoto. E‐mail: hashimot@med.kurume-u.ac.jp Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 168, Issue 4, 1 April 2013, Pages 879–881, https://doi.org/10.1111/bjd.12019 Published: 01 April 2013
Optimality of the genetic code with respect to protein stability and amino-acid frequencies
Authors: Dimitri Gilis, Serge Massar, Nicolas J Cerf, Marianne Rooman
Journal: Genome biology (2001)

The genetic code is known to be efficient in limiting the effect of mistranslation errors. A misread codon often codes for the same amino acid or one with similar biochemical properties, so the structure and function of the coded protein remain relatively unaltered. Previous studies have attempted to address this question quantitatively, by estimating the fraction of randomly generated codes that do better than the genetic code in respect of overall robustness. We extended these results by investigating the role of amino-acid frequencies in the optimality of the genetic code. We found that taking the amino-acid frequency into account decreases the fraction of random codes that beat the natural code. This effect is particularly pronounced when more refined measures of the amino-acid substitution cost are used than hydrophobicity. To show this, we devised a new cost function by evaluating in silico the change in folding free energy caused by all possible point mutations in a set of protein structures. With this function, which measures protein stability while being unrelated to the code's structure, we estimated that around two random codes in a billion (109) are fitter than the natural code. When alternative codes are restricted to those that interchange biosynthetically related amino acids, the genetic code appears even more optimal. These results lead us to discuss the role of amino-acid frequencies and other parameters in the genetic code's evolution, in an attempt to propose a tentative picture of primitive life.
Abstract 416: New technology to detect DNA methylation in plasma sample from lung cancer patients
Authors: Keiko Shinjo, Eisaku Kondo, Yutaka Kondo
Journal: Cancer Research (2014)

Abstract Epigenetic alterations have emerged as a common hallmark of many types of human cancers including lung cancers. Therefore, detection of aberrant DNA methylation from blood samples may be a promising diagnostic tool for cancers. We have been developing a highly sensitive plasma-based approach to detect aberrant DNA methylation in lung cancer patients. First, we identified seven markers from genome-wide methylation analysis, which can diagnose lung cancer in tissue samples with high accuracy (sensitivity, 91%; specificity, 100%). Next, we evaluated DNA methylation status in tissue samples and corresponding plasma samples in each patient using pyrosequencing analysis and qMSP. However, DNA methylation status between tissue and plasma samples were not concordant by both methods (pyrosequencing, 0/19 cases; qMSP, 3/9 cases). Given the concentration of DNA in plasma originated from cancerous tissue might theoretically be very low, we need to use more sensitive and accurate methods. We used digital PCR and next generation sequencer to analyze the methylation status of plasma DNA. These methods are both highly sensitive. Now we invent a new technology using specific probes, which can recognize sequence information including methylated cytosine even in one DNA molecule. This new technology might be applicable as a practical tool for lung cancer diagnosis. Citation Format: Keiko Shinjo, Eisaku Kondo, Yutaka Kondo. New technology to detect DNA methylation in plasma sample from lung cancer patients. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 416. doi:10.1158/1538-7445.AM2014-416
329. Long-Term Transgene Expression by Hepatocytes Transduced with Retroviral Vectors Requires Induction of Immune Tolerance to the Transgene
Authors: Juliana Pupi, Carole Guillonneau, Virginie Picard, Maria C. Cuturi, Nicolas Ferry, Ignacio Anegon
Journal: Molecular Therapy (2004)

Gene therapy of inherited liver disease requires long-term expression of the therapeutic transgene. Recombinant retroviruses are able to integrate into the transduced cell's genome and hence are convenient tools to achieve permanent transgene expression. However, we previously demonstrated that a cytotoxic immune response directed against the transgene product eliminated hepatocytes transduced in vivo using recombinant retroviruses.
"Treatment" Cosmetics: Hype or Help?
Authors: L Lamberg
Journal: JAMA (1998)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Prevalence of symptoms of childhood asthma, allergic rhinoconjunctivitis and eczema in the Pacific: The International Study of Asthma and Allergies in Childhood (ISAAC)
Authors: S. Foliaki, I. Annesi‐Maesano, R. Daniel, T. Fakakovikaetau, M. Magatongia, N. Tuuau‐Potoi, L. Waqatakirewa, S.K. Cheng, N. Pearce
Journal: Allergy (2007)

The International Study of Asthma and Allergies in Childhood (ISAAC) has provided valuable information regarding international prevalence patterns and potential risk factors for asthma, allergic rhinoconjunctivitis and eczema. However, the only Pacific countries that participated in ISAAC Phase I were Australia and New Zealand, and these included only a small number of Pacific children. Phase III has involved not only repeating the Phase I survey to examine time trends, but also to include centres and countries which are of interest but did not participate in Phase I. The ISAAC Phase III study was therefore conducted in the Pacific (in French Polynesia, New Caledonia, Tonga, Fiji Islands, Samoa, Cook Islands, Tokelau Islands and Niue). The overall prevalence rates of current symptoms (in the last 12 months) were 9.9% for asthma, 16.4% for allergic rhinoconjunctivitis and 10.7% for atopic eczema. The prevalence of current wheezing (9.9%) was generally much lower than that has been observed in Pacific children in New Zealand (31%), but there was considerable variation between the various Pacific centres: Tokelau Islands (19.7%), Tonga (16.2%), Niue (12.7%), French Polynesia (11.3%), Cook Islands (10.6%), Fiji Islands (10.4%), New Caledonia (8.2%) and Samoa (5.8%). The reasons for these differences in prevalence across the Pacific are unclear and require further research. The finding that prevalence levels are generally considerably lower than those in Pacific children in New Zealand adds to previous evidence that children who migrate experience an altered risk of asthma as a result of exposure to a new environment during childhood.
Abstract 17919: Cigarette Smoking Explains Excess Deaths Associated with Being Underweight among Middle-Aged Korean Men
Authors: Joo Young Lee, Hyeon Chang Kim, Keeho Park, Song Vogue Ahn, Chulwoo Ahn, Dae Ryong Kang, Il Suh
Journal: Circulation (2014)

Introduction: It is unclear whether smoking affects a relationship between being underweight and the risk of all-cause mortality. Hypothesis: We assessed the hypothesis that smoking causes excess mortality among middle-aged Korean men with low body mass index (BMI). Methods: We analyzed data on the body mass index (BMI), smoking status, and all-cause mortality in a population-based cohort study (108,461 Korean men aged 35-59 years as of 1990 and 1992). To minimize the possibility of reverse causality, we excluded men (1) who had reported to have a disease at baseline, (2) whose information on their smoking status had been missing and (3) who had died in 1993-1995. Finally, 95,019 men were enrolled for analysis. The mean follow-up period was 13.7 years. The BMI was divided into five categories according to WHO criteria for Asians: underweight, <18.5 kg/m2; normal weight, 18.5-22.9 kg/m2; overweight at risk, 23.0-24.9 kg/m2; obese I, 25.0-29.9 kg/m2; obese II, ≥30.0 kg/m2. Smoking status was categorized int...
Rural Communities Struggle With AIDS
Authors: Rebecca Voelker
Journal: JAMA (1998)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Medical Clinics Versus Usual Care for Patients With Both Diabetes and Hypertension
Authors: David Edelman, Sonja K. Fredrickson, Stephanie D. Melnyk, Cynthia J. Coffman, Amy S. Jeffreys, Santanu Datta, George L. Jackson, Amy C. Harris, Natia S. Hamilton, Helen Stewart, Jeannette Stein, Morris Weinberger
Journal: Annals of Internal Medicine (2010)

Group medical clinics (GMCs) are widely used to help manage diabetes and hypertension, but data on their effectiveness are limited. In this randomized trial in 239 patients with comorbid diabetes a...
Coping with loss: Blindness and loss of other sensory and cognitive functions
Authors: R. G Fitzgerald, C. M. Parkes
Journal: BMJ (1998)

This is the fifth in a series of 10 articles dealing with the different types of loss that doctors will meet in their practice

Series editors: Colin Murray Parkes and Andrew Markus

Sensory and cognitive functions enable us to orient ourselves in the world; they make us aware of dangers and rewards; they mediate many sources of pleasure and of pain; and they are the means by which we receive messages from others. Anything that seriously impairs sensory or cognitive function is bound to have profound psychological effects, not only on the person who is affected but also on family, friends, workmates, and caregivers.

#### Summary points

Sensory and cognitive defects disable all who come into contact with them, including doctors

Fear, frustration, and grief are natural reactions in patients and their carers

Denial of loss commonly impairs rehabilitation

Anticipatory guidance and support after the loss can reduce long term problems

Sensory and cognitive losses disable the doctor as well as the patient. When we attempt to communicate with deaf people, their deafness renders us dumb. Blindness in our patients deprives us of the ability to use non-verbal communication. An aphasic person effectively teaches us what it feels like to be deaf. The brain damaged patient makes us feel stupid. We experience the same frustration as they do and some of the same pain.

The situation is particularly hard when the circumstances demand sensitive and empathic communication, for it is this very subtlety that is most difficult to achieve. The fact that, unlike the patient, we can escape from the frustration—by escaping from the patient—encourages us to do just that. We do our duty, inform them of the help that is available, then leave it all to them. We give up trying to communicate, avoid interaction, and inadvertently indicate that we wish they …
Abstract 2659: Increased Cystatin C Serum Levels Improve Risk Stratification in Patients with Acute Coronary Syndrome and Normal Glomerular Filtration Rate
Authors: Jose Garcia-Acuna, Eva Garcia-Babarro, Mario Gutierrez, Jose Ramon Gonzalez-Juanatey
Journal: Circulation (2008)

Use of Cystatin C serum levels (CC) is a more sensible marker of renal function than serum Creatinine levels (Cr) and Glomerular Filtration Rate (GFR). Previous studies have shown that increased serum CC levels with normal GFR in a population with cardiovascular risks factors but without any cardiovascular disease is associated with increased cardiovascular events but this was not analyzed in ischemic heart disease patients. We prospectively studied 203 patients hospitalized with Acute Coronary Syndrome (ACS). Serum CC levels were determined in the first 24 hours of hospitalization in all cases and two groups were identified (&gt;and&lt; 0.95 mg/L). GFR was calculated by MDRD formulation using the first serum Cr determination in all patients and were established two groups (&gt; and &lt; 60 ml/min/1.73m2). Coronariography was performed in all patients. During 13 months follow-up period we analyzed Mayor Adverse Coronary Events (MACE) and Mortality. Patients with serum CC levels &gt;0.95 were older, with higher hypertension prevalence, prior stroke, high frequency of renal disease and greater severity of coronary artery disease (42% patients with three-vessel coronary artery disease, p=0.05). During the follow-up these patients showed a significantly higher risk of heart failure new-onset (62% p=0.001) and mortality (14 %, p=0.001). Patients with GFR &gt;60 and serum CC levels &lt;0.95 presented significantly higher values of MACE (61%; p=0.001) and mortality (8%; p=0.001) in opposition to 18% and 3% respectively in the group of patients with GFR 3 60 and serum CC levels 30.95. Nevertheless significant prognostic differences between GFR &gt;60 and serum CC levels &lt;0.95 group and GFR &gt;60 and serum CC levels &gt;0.95 group were observed. In the multivariate analysis was observed than serum CC levels was an independent predictor to develop of new-onset heart failure (RR: 3.9 CI 95% 1.5–9.9; p=0.002), and mortality (RR: 2. CI 95% 1.2–3.6, p=0.001) during the follow-up. Serum CC levels are a powerful both mortality and heart failure predictor in patients with high risk ACS. High serum CC levels in patients with ACS and normal renal function identify a higher risk group. Serum CC determination may be include in the risk evaluation of patients with ACS.
The biological profile of PD 0325901: A second generation analog of CI-1040 with improved pharmaceutical potential
Authors: Judith S. Sebolt-Leopold, Ronald Merriman, Charles Omer, Haile Tecle, Alex Bridges, Wayne Klohs, Cho-Ming Loi, Heather Valik, Sally Przybranowski, Mark Meyer, W. R. Leopold
Journal: Cancer Research (2004)

4003  CI-1040, the first MEK inhibitor to enter clinical evaluation, was advanced into development based on promising preclinical activity. While Phase 1 data pointed to promising hints of clinical activity, efficacy in Phase 2 single agent screening studies was insufficient to warrant continued development. Target suppression in Phase 1 tumor biopsies was  50% at 24 hours post-dosing. In comparison, CI-1040 at a much higher dose (150 mg/kg) could only inhibit pERK levels for roughly 8 hours, returning to control levels by 24 hours after treatment. Oral efficacy comparisons revealed that the dose required to produce a 70% incidence of complete tumor responses (C26 model) was 25 mg/kg/day versus 900 mg/kg/day for PD0325901 and CI-1040, respectively. Anticancer activity of PD 0325901 has been demonstrated for a broad spectrum of human tumor xenografts, significantly inhibiting the growth of 6 out of 7 human tumor models tested. PD 0325901 was also shown to be highly efficacious and effective at inhibiting ERK phosphorylation when administered by the IV route. The improved anticancer activity of PD0325901 compared to CI-1040 is likely due to several contributing pharmacological factors, including longer duration and greater potency of MEK inhibition, as well as greater solubility leading to improved bioavailability, and increased metabolic stability. Based on its highly specific inhibition of MEK and its overall pharmaceutical profile, PD0325901 has the potential to provide ultimate validation of MEK as an anticancer drug target. Phase 1 trials with this agent are underway.
Stem cell therapies for recessive dystrophic epidermolysis bullosa
Authors: A. Petrova, D. Ilic, J.A. McGrath
Journal: British Journal of Dermatology (2010)

Journal Article Stem cell therapies for recessive dystrophic epidermolysis bullosa Get access A. Petrova, A. Petrova St John's Institute of Dermatology, Dermatology Research Laboratories, Floor 9 Tower Wing, Guy's Hospital, Great Maze Pond, London SE1 9RT, U.K.Assisted Conception Unit, King's College London (Guy's Campus), London, U.K. Search for other works by this author on: Oxford Academic Google Scholar D. Ilic, D. Ilic Assisted Conception Unit, King's College London (Guy's Campus), London, U.K. Search for other works by this author on: Oxford Academic Google Scholar J.A. McGrath J.A. McGrath St John's Institute of Dermatology, Dermatology Research Laboratories, Floor 9 Tower Wing, Guy's Hospital, Great Maze Pond, London SE1 9RT, U.K. Correspondence: John McGrath. E‐mail: john.mcgrath@kcl.ac.uk Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 163, Issue 6, 1 December 2010, Pages 1149–1156, https://doi.org/10.1111/j.1365-2133.2010.09981.x Published: 01 December 2010
Abstract 17272: Ionic Current Remodeling Delays the Electrical Recovery of the Senescent Heart
Authors: Sergio Signore, Giulia Borghetti, Ramaswamy Kannappan, Andrea Sorrentino, Antonio Cannata, Marianna Meo, Yu Zhou, Chiara Mangiaracina, Nicola Alesi, Brena F Sena, Matthias Nahrendorf, Polina Goichberg, Annarosa Leri, Piero Anversa, Marcello Rota
Journal: Circulation (2014)

Cardiac aging is associated with lengthening of the QT interval, a condition that enhances malignant ventricular arrhythmias and sudden death. The aim of this study was to establish whether ionic currents are altered in old myocytes contributing to the protracted electrical recovery of the senescent heart. Thus, mice at 3-30 months of age were studied by ECG and patch-clamp; these physiological determinations were complemented with molecular assays for the analysis of ion channel proteins. By surface ECG and telemetry system, PR, QRS and QT intervals were prolonged in mice at 25 months or older. These delays were maintained in ex-vivo Langendorff preparations. In comparison to young, epicardial monophasic action potential (AP) duration at 50% and 90% repolarization were 1.6- and 1.2-fold larger in old LV, respectively. Moreover, senescent hearts presented a 60% higher incidence of arrhythmias. In isolated myocytes, prolongation of the early (+47%), intermediate (+117%) and late (+75%) repolarization phases of the AP were identified in cells from old animals, whereas resting membrane potential, upstroke amplitude and +dV/dt were preserved. Voltage-clamp experiments were then performed to measure ionic current properties. The rapidly activating K+ current, which consists of the transient outward and ultrarapid delayed rectifier (Ito+Kur), is responsible for the early repolarization of the AP, and was significantly reduced in old myocytes. Molecular studies revealed low levels of transcripts and proteins for K+ channel subunits Kv1.4, Kv1.5 and KChiP2 in senescent cells. Also, the late Na+ current INaL, which presents slow inactivation kinetics and is operative during AP repolarization, was 1.5-fold larger in old cells. These changes were associated with alterations in gene and protein expression of Na+ channel subunits. Inhibition of INaL with mexiletine significantly shortened the intermediate and late repolarization phases of the AP in both myocytes and perfused myocardium from old mice. Importantly, INaL inhibition in vivo shortened the QT interval of senescent mice by 12%. Thus, defects in ionic current occur with aging resulting in prolongation of the AP and delays in electrical recovery which may lead to malignant ventricular arrhythmias.
Detection of High-Risk Atherosclerotic Plaque
Authors: Jerome L. Fleg, Gregg W. Stone, Zahi A. Fayad, Juan F. Granada, Thomas S. Hatsukami, Frank D. Kolodgie, Jacques Ohayon, Roderic Pettigrew, Marc S. Sabatine, Guillermo J. Tearney, Sergio Waxman, Michael J. Domanski, Pothur R. Srinivas, Jagat Narula
Journal: JACC. Cardiovascular imaging (2012)